Recent Progress and Opportunities for Nucleic Acid Aptamers.
Recent Progress and Opportunities for Nucleic Acid Aptamers.
复制标题
DOI：
10.3390/life11030193
复制
发表时间：
2021-02-28
期刊：
影响因子：
--
通讯作者：
Byun J
中科院分区：
文献类型：
--
作者：
Byun J
三十年前创造的适体和定向进化一词现已成熟。核酸作为配体调节靶蛋白活性的概念源于病毒的基础科学研究。适体是能够进行特异性、高亲和力分子结合的短核酸序列，可用于治疗和诊断应用。与传统抗体相比，适配体具有尺寸小、结构灵活、生物相容性好、免疫原性低等优点。体外选择方法用于从随机寡核苷酸文库中分离对所需靶标具有特异性的适体。第一个适配体药物Macugen于2004年获得FDA批准，随之而来的是针对各种靶点和疾病的多项研究和临床调查。尽管前景广阔，但大多数适配体未能满足人体临床试验中必要的安全性和有效性标准。在这些挫折中，新技术的出现以及适体和配体指数富集系统进化（SELEX）设计的最新进展正在为这一领域带来希望。在 COVID-19 时代，适配体的独特特性重新引起人们的兴趣。适体的结合性能和重现性仍然是解决当前临床转化障碍的关键问题。有必要对不同条件下的适体结合和构象动力学进行彻底分析。在此，回顾了适配体的挑战和机遇以及最新进展。
Coined three decades ago, the term aptamer and directed evolution have now reached their maturity. The concept that nucleic acid could modulate the activity of target protein as ligand emerged from basic science studies of viruses. Aptamers are short nucleic acid sequences capable of specific, high-affinity molecular binding, which allow for therapeutic and diagnostic applications. Compared to traditional antibodies, aptamers have several advantages, including small size, flexible structure, good biocompatibility, and low immunogenicity. In vitro selection method is used to isolate aptamers that are specific for a desired target from a randomized oligonucleotide library. The first aptamer drug, Macugen, was approved by FDA in 2004, which was accompanied by many studies and clinical investigations on various targets and diseases. Despite much promise, most aptamers have failed to meet the requisite safety and efficacy standards in human clinical trials. Amid these setbacks, the emergence of novel technologies and recent advances in aptamer and systematic evolution of ligands by exponential enrichment (SELEX) design are fueling hope in this field. The unique properties of aptamer are gaining renewed interest in an era of COVID-19. The binding performance of an aptamer and reproducibility are still the key issues in tackling current hurdles in clinical translation. A thorough analysis of the aptamer binding under varying conditions and the conformational dynamics is warranted. Here, the challenges and opportunities of aptamers are reviewed with recent progress.
登录
查看更多内容
影响因子：
3.7
作者：
Gold L;Ayers D;Bertino J;Bock C;Bock A;Brody EN;Carter J;Dalby AB;Eaton BE;Fitzwater T;Flather D;Forbes A;Foreman T;Fowler C;Gawande B;Goss M;Gunn M;Gupta S;Halladay D;Heil J;Heilig J;Hicke B;Husar G;Janjic N;Jarvis T;Jennings S;Katilius E;Keeney TR;Kim N;Koch TH;Kraemer S;Kroiss L;Le N;Levine D;Lindsey W;Lollo B;Mayfield W;Mehan M;Mehler R;Nelson SK;Nelson M;Nieuwlandt D;Nikrad M;Ochsner U;Ostroff RM;Otis M;Parker T;Pietrasiewicz S;Resnicow DI;Rohloff J;Sanders G;Sattin S;Schneider D;Singer B;Stanton M;Sterkel A;Stewart A;Stratford S;Vaught JD;Vrkljan M;Walker JJ;Watrobka M;Waugh S;Weiss A;Wilcox SK;Wolfson A;Wolk SK;Zhang C;Zichi D
通讯作者：
Zichi D
影响因子：
16.6
作者：
Del Grosso, Erica;Ragazzon, Giulio;Ricci, Francesco
通讯作者：
Ricci, Francesco
影响因子：
5.8
作者：
Baneshi, Marzieh;Dadfarnia, Shayessteh;Bardania, Hassan
通讯作者：
Bardania, Hassan
影响因子：
2.7
作者：
Chandola, Chetan;Casteleijn, Marco G.;Neerathilingam, Muniasamy
通讯作者：
Neerathilingam, Muniasamy
影响因子：
2.7
作者：
Bruno, John G.;Carrillo, Maria P.;Hanson, Douglas
通讯作者：
Hanson, Douglas